Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
Paul E. Goss(Massachusetts General Hospital), Ian E. Smith(Royal Marsden Hospital), Joyce O’Shaughnessy(Texas Oncology), Bent Ejlertsen(Rigshospitalet), Manfred Kaufmann(Goethe University Frankfurt), Frances Boyle(Mater Health Services), Aman U. Buzdar(The University of Texas MD Anderson Cancer Center), P. Fumoleau(Centre Georges François Leclerc), William J. Gradishar(Northwestern University), Miguel Martín(Hospital General Universitario Gregorio Marañón), Beverly Moy(Massachusetts General Hospital), Martine Piccart(Institut Jules Bordet), Kathleen I. Pritchard(University of Toronto), Deborah Lindquist(Arizona Oncology), Yanin Chávarri-Guerra(Massachusetts General Hospital), Gursel Aktan(GlaxoSmithKline (United States)), Erica Rappold(GlaxoSmithKline (United States)), Lisa S. Williams(GlaxoSmithKline (United Kingdom)), Dianne M. Finkelstein(Massachusetts General Hospital)
Cited by 131